232 related articles for article (PubMed ID: 37251935)
1. Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Shi D; Li Y; Liang X; Chen L
Front Oncol; 2023; 13():1162360. PubMed ID: 37251935
[TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US.
Chen J; Han M; Liu A; Shi B
Front Oncol; 2021; 11():734594. PubMed ID: 34778047
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
Shi D; Liang X; Li Y; Chen L
PLoS One; 2023; 18(8):e0290507. PubMed ID: 37616309
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Li Y; Liang X; Li H; Yang T; Guo S; Chen X
Front Pharmacol; 2022; 13():906956. PubMed ID: 35928269
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.
Lang Y; Chai Q; Tao W; Liao Y; Liu X; Wu B
Breast; 2023 Apr; 68():173-180. PubMed ID: 36780838
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
[TBL] [Abstract][Full Text] [Related]
7. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer.
Xie J; Li S; Li Y; Li J
BMC Health Serv Res; 2023 Jun; 23(1):706. PubMed ID: 37386633
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis.
Dong L; Lin S; Zhong L; Nian D; Li Y; Wang R; Zhou W; Weng X; Xu X
Clin Breast Cancer; 2022 Jan; 22(1):e21-e29. PubMed ID: 34238670
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Oncol; 2023; 13():1113374. PubMed ID: 37182130
[TBL] [Abstract][Full Text] [Related]
11. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
Berrios K; Burum A; Jeong E; Zhong L
J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
[No Abstract] [Full Text] [Related]
12. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X
Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States.
Peng Y; Wang L; Peng L; Liu Q; Yi L; Luo X; Li S; Qin S; Wan X; Tan C; Chen G
Clin Ther; 2023 Oct; 45(10):965-972. PubMed ID: 37537015
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.
Cher BP; Goh S; Aziz MIA; Wong G; Ng Chee Hui R; Ong BS; Ng KH
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):217-225. PubMed ID: 38149409
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.
Li Y; Liang X; Yang T; Guo S; Chen X
Front Oncol; 2022; 12():878054. PubMed ID: 36226060
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis.
Zeng N; Han J; Liu Z; He J; Tian K; Chen N
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444496
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
20. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
